GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » PEG Ratio

Repligen (Repligen) PEG Ratio : 3.09 (As of Apr. 25, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Repligen PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Repligen's PE Ratio without NRI is 95.76. Repligen's 5-Year EBITDA growth rate is 31.00%. Therefore, Repligen's PEG Ratio for today is 3.09.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Repligen's PEG Ratio or its related term are showing as below:

RGEN' s PEG Ratio Range Over the Past 10 Years
Min: 0.88   Med: 3.37   Max: 25.32
Current: 3.09


During the past 13 years, Repligen's highest PEG Ratio was 25.32. The lowest was 0.88. And the median was 3.37.


RGEN's PEG Ratio is ranked worse than
66.27% of 249 companies
in the Medical Devices & Instruments industry
Industry Median: 1.8 vs RGEN: 3.09

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Repligen PEG Ratio Historical Data

The historical data trend for Repligen's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen PEG Ratio Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.87 4.24 2.13 0.97 2.70

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.06 1.08 1.71 2.70

Competitive Comparison of Repligen's PEG Ratio

For the Medical Instruments & Supplies subindustry, Repligen's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's PEG Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Repligen's PEG Ratio falls into.



Repligen PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Repligen's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=95.757225433526/31.00
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Repligen  (NAS:RGEN) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Repligen PEG Ratio Related Terms

Thank you for viewing the detailed overview of Repligen's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines

From GuruFocus

Repligen Corporation to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-04-2022

Repligen Corporation to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-24-2022

Repligen Corporation to Present at Upcoming Investor Conferences

By sperokesalga sperokesalga 05-31-2023

Repligen Appoints Martin D. Madaus to Board of Directors

By sperokesalga sperokesalga 02-09-2023

Repligen to Report Second Quarter 2022 Financial Results

By PurpleRose PurpleRose 07-19-2022

Repligen To Host Investor Day 2022

By PurpleRose PurpleRose 08-24-2022

Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

By GuruFocusNews GuruFocusNews 06-25-2022